Investigating the effect of vitamin D3 supplementation on inflammatory factors such as HIF, EGF, VEGF in diabetic nephropathy

Investigating the effect of vitamin D3 supplementation on inflammatory factors such as HIF, EGF, VEGF in mild and moderate diabetic nephropathy with a double-blind randomized clinical trial with placebo control

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180922041089N5

Enrollment

Registered

2025-03-10

Start date

2024-11-21

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic nephropathy. Type 2 diabetes mellitus with diabetic nephropathy

Interventions

Intervention 1: Intervention group: including 21 patients with diabetic nephropathy who will receive 50,000 vitamin D pills every week for 12 weeks. Intervention 2: Control group: including 21 patient

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Being 20 to 60 years old Examination of mild and moderate nephropathy Deficiency or marginal state of vitamin D Informed consent Having a BMI less than 30 People with type 2 diabetes who are treated with insulin and oral antidiabetic drugs GFR between 90 and 30

Exclusion criteria

Exclusion criteria: Any history of alcohol and tobacco use Breastfeeding and pregnancy or the intention of pregnancy within the next three months Pathological conditions affecting the kidneys, such as the use of antibiotics, NSAIDs, corticosteroids, hormonal drugs, heart failure, uncontrolled blood pressure, cystic kidney diseases, prostate enlargement, kidney stones and the presence of any diagnosed neoplasia or malignancy and concomitant autoimmune diseases. Use of vitamin D supplements and antioxidants in the last three months BMI>30 and severe albuminuria (ACR>300) Type 1 diabetes

Design outcomes

Primary

Measure	Time frame
Inflammatory factor EGF. Timepoint: At the beginning and end of the study. Method of measurement: blood test.;Inflammatory factor HIF. Timepoint: At the beginning and end of the study. Method of measurement: blood test.;Inflammatory factor VEGF. Timepoint: At the beginning and end of the study. Method of measurement: blood test.	—

Secondary

Measure	Time frame
ESR. Timepoint: The beginning and end of the study. Method of measurement: blood test.;URIC ACID. Timepoint: The beginning and end of the study. Method of measurement: blood test.;CRP. Timepoint: The beginning and end of the study. Method of measurement: blood test.;FERRITIN. Timepoint: The beginning and end of the study. Method of measurement: blood test.;PLATELET. Timepoint: The beginning and end of the study. Method of measurement: blood test.	—

Measure

Time frame

ESR. Timepoint: The beginning and end of the study. Method of measurement: blood test.;URIC ACID. Timepoint: The beginning and end of the study. Method of measurement: blood test.;CRP. Timepoint: The beginning and end of the study. Method of measurement: blood test.;FERRITIN. Timepoint: The beginning and end of the study. Method of measurement: blood test.;PLATELET. Timepoint: The beginning and end of the study. Method of measurement: blood test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbolfazl Zendehdel

Tehran University of Medical Sciences

azendedel@sina.tums.ac.ir+98 21 5517 6031

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026